Puk Meijs-Hermanns, Henrica M J Werner, Loes Kooreman, Petra Bretová, Vit Weinberger, Stephanie Vrede, Luthy S M Alcala, Frédéric Amant, Jasmin Asberger, Markéta Bednaříková, Dorry Boll, Carolien M Bronkhorst, Johan Bulten, Antonio Gil-Moreno, Ingfrid S Haldorsen, Jitka Hausnerová, Jutta Huvila, Martin Koskas, Camilla Krakstad, Heidi Küsters-Vandevelde, Gemma Mancebo Moreno, Xavier Matias-Guiu, Huy Ngo, Brenda M Pijlman, Maria Santacana, Marieke Smink, Jone Trovik, Viola M J Verhoef, Koen Van de Vijver, Dennis van Hamont, Anneke A M van der Wurff, Johanna M A Pijnenborg, Nicole C M Visser
{"title":"改进术前分级:2级子宫内膜样癌中p53和PR表达的相关性。","authors":"Puk Meijs-Hermanns, Henrica M J Werner, Loes Kooreman, Petra Bretová, Vit Weinberger, Stephanie Vrede, Luthy S M Alcala, Frédéric Amant, Jasmin Asberger, Markéta Bednaříková, Dorry Boll, Carolien M Bronkhorst, Johan Bulten, Antonio Gil-Moreno, Ingfrid S Haldorsen, Jitka Hausnerová, Jutta Huvila, Martin Koskas, Camilla Krakstad, Heidi Küsters-Vandevelde, Gemma Mancebo Moreno, Xavier Matias-Guiu, Huy Ngo, Brenda M Pijlman, Maria Santacana, Marieke Smink, Jone Trovik, Viola M J Verhoef, Koen Van de Vijver, Dennis van Hamont, Anneke A M van der Wurff, Johanna M A Pijnenborg, Nicole C M Visser","doi":"10.1016/j.ijgc.2025.101682","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the association between pre-operative progesterone receptor (PR) and p53 expression and prognosis in pre-operative grade 2 endometrioid endometrial carcinoma compared with grade 1 and grade 3 carcinomas.</p><p><strong>Methods: </strong>Three European endometrial carcinoma cohort studies were included. Patients with pre-operative grade 2 endometrioid carcinoma and known pre-operative PR and p53 status were included (n = 400), as were patients with pre-operative grade 1 (n = 602) or grade 3 (n = 148) endometrioid carcinomas. Kaplan-Meier and Cox regression analyses were performed to analyze disease-specific and disease-free survival.</p><p><strong>Results: </strong>Patients with pre-operative grade 2 endometrial carcinoma and wild-type p53 plus PR-positive expression showed a similar 7-year disease-specific survival to grade 1 endometrial carcinoma patients (95.8% vs 97.5%, p = .13), while the 7-year disease-specific survival of patients with grade 2 endometrial carcinoma with p53 aberrant and/or negative PR expression (83.5%) was significantly lower (p < .001). The combination of these markers was an independent prognostic factor in multivariate Cox regression analyses.</p><p><strong>Conclusions: </strong>The prognostic impact of pre-operative p53 and PR expression in patients with grade 2 endometrioid endometrial carcinoma supports a modified binary grading system in which grade 2 patients should be pre-operatively classified as low- or high-grade depending on p53 and PR expression.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101682"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Improving pre-operative binary grading: relevance of p53 and PR expression in grade 2 endometrioid endometrial carcinoma.\",\"authors\":\"Puk Meijs-Hermanns, Henrica M J Werner, Loes Kooreman, Petra Bretová, Vit Weinberger, Stephanie Vrede, Luthy S M Alcala, Frédéric Amant, Jasmin Asberger, Markéta Bednaříková, Dorry Boll, Carolien M Bronkhorst, Johan Bulten, Antonio Gil-Moreno, Ingfrid S Haldorsen, Jitka Hausnerová, Jutta Huvila, Martin Koskas, Camilla Krakstad, Heidi Küsters-Vandevelde, Gemma Mancebo Moreno, Xavier Matias-Guiu, Huy Ngo, Brenda M Pijlman, Maria Santacana, Marieke Smink, Jone Trovik, Viola M J Verhoef, Koen Van de Vijver, Dennis van Hamont, Anneke A M van der Wurff, Johanna M A Pijnenborg, Nicole C M Visser\",\"doi\":\"10.1016/j.ijgc.2025.101682\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aimed to evaluate the association between pre-operative progesterone receptor (PR) and p53 expression and prognosis in pre-operative grade 2 endometrioid endometrial carcinoma compared with grade 1 and grade 3 carcinomas.</p><p><strong>Methods: </strong>Three European endometrial carcinoma cohort studies were included. Patients with pre-operative grade 2 endometrioid carcinoma and known pre-operative PR and p53 status were included (n = 400), as were patients with pre-operative grade 1 (n = 602) or grade 3 (n = 148) endometrioid carcinomas. Kaplan-Meier and Cox regression analyses were performed to analyze disease-specific and disease-free survival.</p><p><strong>Results: </strong>Patients with pre-operative grade 2 endometrial carcinoma and wild-type p53 plus PR-positive expression showed a similar 7-year disease-specific survival to grade 1 endometrial carcinoma patients (95.8% vs 97.5%, p = .13), while the 7-year disease-specific survival of patients with grade 2 endometrial carcinoma with p53 aberrant and/or negative PR expression (83.5%) was significantly lower (p < .001). The combination of these markers was an independent prognostic factor in multivariate Cox regression analyses.</p><p><strong>Conclusions: </strong>The prognostic impact of pre-operative p53 and PR expression in patients with grade 2 endometrioid endometrial carcinoma supports a modified binary grading system in which grade 2 patients should be pre-operatively classified as low- or high-grade depending on p53 and PR expression.</p>\",\"PeriodicalId\":14097,\"journal\":{\"name\":\"International Journal of Gynecological Cancer\",\"volume\":\" \",\"pages\":\"101682\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Gynecological Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijgc.2025.101682\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecological Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijgc.2025.101682","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究旨在评价术前2级子宫内膜样癌与1级和3级子宫内膜癌术前孕激素受体(PR)和p53表达与预后的关系。方法:纳入三项欧洲子宫内膜癌队列研究。术前2级子宫内膜样癌和已知术前PR和p53状态的患者(n = 400),以及术前1级子宫内膜样癌(n = 602)或3级子宫内膜样癌(n = 148)患者。Kaplan-Meier和Cox回归分析分析疾病特异性生存和无病生存。结果:术前p53野生型+ PR阳性表达的2级子宫内膜癌患者的7年疾病特异性生存率与1级子宫内膜癌患者相似(95.8% vs 97.5%, p = .13),而p53异常和/或PR阴性表达的2级子宫内膜癌患者的7年疾病特异性生存率(83.5%)显著低于1级子宫内膜癌患者(p < .001)。在多变量Cox回归分析中,这些指标的组合是一个独立的预后因素。结论:术前p53和PR表达对2级子宫内膜样癌患者预后的影响支持改进的二元分级系统,其中2级患者术前应根据p53和PR表达分为低级别或高级别。
Improving pre-operative binary grading: relevance of p53 and PR expression in grade 2 endometrioid endometrial carcinoma.
Objective: This study aimed to evaluate the association between pre-operative progesterone receptor (PR) and p53 expression and prognosis in pre-operative grade 2 endometrioid endometrial carcinoma compared with grade 1 and grade 3 carcinomas.
Methods: Three European endometrial carcinoma cohort studies were included. Patients with pre-operative grade 2 endometrioid carcinoma and known pre-operative PR and p53 status were included (n = 400), as were patients with pre-operative grade 1 (n = 602) or grade 3 (n = 148) endometrioid carcinomas. Kaplan-Meier and Cox regression analyses were performed to analyze disease-specific and disease-free survival.
Results: Patients with pre-operative grade 2 endometrial carcinoma and wild-type p53 plus PR-positive expression showed a similar 7-year disease-specific survival to grade 1 endometrial carcinoma patients (95.8% vs 97.5%, p = .13), while the 7-year disease-specific survival of patients with grade 2 endometrial carcinoma with p53 aberrant and/or negative PR expression (83.5%) was significantly lower (p < .001). The combination of these markers was an independent prognostic factor in multivariate Cox regression analyses.
Conclusions: The prognostic impact of pre-operative p53 and PR expression in patients with grade 2 endometrioid endometrial carcinoma supports a modified binary grading system in which grade 2 patients should be pre-operatively classified as low- or high-grade depending on p53 and PR expression.
期刊介绍:
The International Journal of Gynecological Cancer, the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.